{"id":"W4249692483","doi":"10.1016/j.clgc.2020.06.002","title":"Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study","year":2020,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Guardant Health; Janssen Pharmaceuticals; Janssen Biotech; Bristol-Myers Squibb Canada; EMD Serono; Genentech; Astellas Pharma; Eisai; Daiichi-Sankyo; Aileron Therapeutics; CTI Biopharma; ImmunoGen; Mirati Therapeutics; Bayer Fund; Five Prime Therapeutics; Acceleron; Clovis Oncology; TG Therapeutics; AstraZeneca; Novocure; Sanofi Genzyme; Takeda Pharmaceuticals U.S.A.; Immunocore; AbbVie; Karyopharm Therapeutics; Exelixis; MedImmune; Sanofi; Celgene; Novartis; Merck; GlaxoSmithKline; Roche; Foundation Medicine; Astellas Pharma US; American Society of Clinical Oncology; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; Boston Biomedical; Pfizer; Amgen; Boehringer Ingelheim; Calithera Biosciences; Bayer; Sarah Cannon Research Institute","keywords":"Medicine; Internal medicine; Nivolumab; Renal cell carcinoma; Rash; Clinical endpoint; Regimen; Clear cell renal cell carcinoma; Progression-free survival; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cancer; Toxicity; Chemotherapy; Clinical trial; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001786221,0.0003590216,0.0007009305,0.0001572589,0.0002269561,0.0005686914,0.0004177695,0.000467127,0.001455132],"category_scores_gemma":[0.001048221,0.0001518973,0.0006612984,0.0001854307,0.0002975205,0.0002542613,0.0001928239,0.0006973871,0.0003187465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001082531,"about_ca_system_score_gemma":0.001407606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001784506,"about_ca_topic_score_gemma":0.003483774,"domain_scores_codex":[0.999585,0.0002005422,0.0000278473,0.0000580949,0.00008540237,0.00004307282],"domain_scores_gemma":[0.9991028,0.0001911851,0.0002414309,0.00007794477,0.0001337993,0.0002528584],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4282529,0.0146535,0.2580428,0.001861386,0.004983058,0.0004081577,0.0004296582,0.004604443,0.07182655,0.0003590425,0.01035703,0.2042214],"study_design_scores_gemma":[0.1752148,0.2486496,0.528685,0.0002201377,0.003507047,0.001102783,0.0001716871,0.004916673,0.01794133,0.0003844869,0.01910301,0.0001034554],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954998,0.002289449,0.0001396518,0.0001091783,0.00001876508,0.0002625723,0.0007740791,0.00002048169,0.0008859588],"genre_scores_gemma":[0.9957444,0.0006728419,0.000365174,0.0002866919,0.00003310812,0.0001882389,0.002189872,0.000008456814,0.0005110948],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001786221,"threshold_uncertainty_score":0.009446561,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03801789324814368,"score_gpt":0.3212636307632831,"score_spread":0.2832457375151394,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}